Jane Antony - Concepedia

Author

Jane Antony

Stanford University ORCID

Also Known As

Antony, Jane, Benjamin Beyersdorf, J Antony, J. Antony, Jan Antony, Jane Antony, Kyle J. Travaglini

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Stanford University Chan Zuckerberg Initiative (United States)University of California, San Francisco Stanford Medicine Neurosciences Institute

About

Jane Antony is an author at Stanford University specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.9K
2	Cell Biology	3	3	1.3K
3	Engineering	1	1	44
4	Computer Science	1	1	44
5	Data Science	1	1	44

Jane Antony

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
A single-cell transcriptomic atlas characterizes ageing tissues in the mouse Nicole Almanzar, Jane Antony, Ankit S. Baghel, Nature Cell LineageDevelopmental BiologySingle-cell Transcriptomic AtlasSingle Cell SequencingMedicine	2020	1.2K
Ageing hallmarks exhibit organ-specific temporal signatures Nicholas Schaum, Benoit Lehallier, Oliver Hãhn, Nature Signal TransductionAgingDevelopmental BiologyLongevityCellular Senescence	2020	644
Molecular hallmarks of heterochronic parabiosis at single-cell resolution Róbert Pálovics, Andreas Keller, Nicholas Schaum, Nature	2022	134
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer Jane Antony, Tuan Zea Tan, Zoe Kelly, Science Signaling	2016	116
Adversarial domain translation networks for integrating large-scale atlas-level single-cell datasets Jia Zhao, Gefei Wang, Jingsi Ming, Nature Computational Science Artificial IntelligenceEngineeringMachine LearningDeep LearningData Science	2022	44
The tumour suppressor <scp>OPCML</scp> promotes <scp>AXL</scp> inactivation by the phosphatase <scp>PTPRG</scp> in ovarian cancer Jane Antony, Elisa Zanini, Zoe Kelly, EMBO Reports Signal TransductionSignaling PathwayMedicineGynecologyCancer Cell Biology	2018	32
The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer Elisa Zanini, Louay Louis, Jane Antony, Molecular Cancer Therapeutics	2017	27
LEFTY1 Is a Dual-SMAD Inhibitor that Promotes Mammary Progenitor Growth and Tumorigenesis Maider Zabala, Neethan A. Lobo, Jane Antony, Cell stem cell MedicineDual-smad InhibitorBreast CancerMammary Progenitor GrowthSystems Biology	2020	17
Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions James R. Birtley, Mohammad N. Alomary, Elisa Zanini, Nature Communications	2019	16
Targeting the AXL signaling pathway in ovarian cancer Ruby Yun‐Ju Huang, Jane Antony, Tuan Zea Tan, Molecular & Cellular Oncology	2016	13

Page 1